BioCentury | Oct 2, 2020

Next stop IPO? Olema adds to momentum with $85M series C

Two weeks after former AstraZeneca CMO Sean Bohen took over as president and CEO, Olema has raised $85 million in a series C round led by Vivo Capital. The San Francisco company’s next financing may well...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

Two months after closing a $54 million series B round, breast cancer company Olema has followed up a flurry of executive hires with the addition of former AstraZeneca CMO Sean Bohen as president and CEO. ...
BioCentury | Sep 16, 2020

Sept. 15 Quick Takes: NIH consortium seeks schizophrenia biomarkers; plus Boehringer-Click, Takeda, Nestlé-Aimmune, 89bio, Cellinta, Cullinan Florentine, Bayer-Systems Oncology

NIH launches Accelerating Medicines Partnership for schizophreniaNIH has partnered with FDA, non-profits and biopharmas to launch the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) initiative...
BioCentury | Aug 22, 2020

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

Kymera’s upsized IPO and 66% gain underscore investors’ continuing appetite for both protein degradation companies and preclinical plays. The offering comes as key milestones approach for protein degradation...
BioCentury | Aug 8, 2020
Translation in Brief

Cocrystal’s COVID-19 antivirals; plus a portable breast cancer diagnostic, Tarveda mini-drug conjugate for solid tumors, and more

...alpha polypeptide (PIK3CA) (p110alpha) Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu) Estrogen receptor 1 (ER) (ESR1) Estrogen receptor 2 (ESR2) Progesterone...
BioCentury | Jul 24, 2020

Olema aims to deploy $54M round to carve its niche in breast cancer to develop OP-1250, a small molecule complete estrogen receptor antagonist (CERAN) targeting ER and ESR2...
...4 CDK6 - Cyclin dependent kinase 6 ER (ESR1) - Estrogen receptor 1 ESR2 - Estrogen receptor 2...
...Henderson Investors Cormorant Asset Management RA Capital Management Wellington Management Surveyor Capital Venrock Associates Foresite Capital Management AstraZeneca plc Estrogen receptor 1 (ER) (ESR1) Estrogen receptor 2 (ESR2) Epidermal...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

Carving a space in the crowded multiple myeloma market for recently approved Sarclisa is one of the four pillars of Sanofi’s strategy for re-entering oncology, and the company believes new data strengthen the case for...
BioCentury | May 13, 2020
Product Development

Arvinas unveils first efficacy signal for targeted protein degradation, points to opportunity in resistant cancers

Arvinas’ top-line ASCO data provides the first evidence that targeted protein degraders can benefit patients, in particular those whose tumors have become resistant to standard therapies. Founded by targeted degradation pioneer Craig Crews in 2013,...
BioCentury | Mar 12, 2020
Product Development

Targeted degradation gets another bump with Kymera’s $102M raise

It’s a big year for targeted protein degraders, and Kymera is adding to the momentum with a $102 million series C round that should bring its first three programs into the clinic. Biotechnology Value Fund...
BioCentury | Dec 11, 2019
Product Development

The writing has been on the wall for Sanofi’s diabetes, CV business for years

One hundred days after taking the helm as CEO, Paul Hudson has outlined a plan to get Sanofi to 30% margins by 2022 that hinges largely on the success of Dupixent and five other priority...
Items per page:
1 - 10 of 995